allogeneic hematopoietic stem cells (St. Jude Children's Research Hospital)

Allogeneic hematopoietic stem cell transplantation (HSCT) is a cellular therapy utilized as a curative treatment for malignant infantile osteopetrosis (MIOP), a rare and fatal genetic disorder characterized by dysfunctional osteoclasts and impaired bone remodeling. In the protocol developed by St. Jude Children's Research Hospital, hematopoietic stem cells are typically sourced from a haploidentical (partially matched) parental donor when a matched sibling is unavailable. These donor cells are processed using the Miltenyi Biotec CliniMACS device for T-cell depletion to facilitate engraftment while minimizing the risk of graft-versus-host disease (GVHD). Following a conditioning regimen, the infused stem cells engraft in the recipient's bone marrow and differentiate into functional osteoclasts, which restore the bone's ability to regulate resorption and remodeling.

Other names

haploidentical hematopoietic stem cellsT-cell depleted hematopoietic stem cellsallogeneic hematopoietic stem cell transplantation